Currently, there are no US consensus on best clinical practice guidelines that incorporate multispecialty recommendations for evaluating cognitive impairment that are thought to be due to Alzheimer’s disease and Related Dementias (ADRD) for use by physicians and nurse practitioners.
Thinning of the retinal nerve fiber layer has been linked to worsening cognitive function and may be valuable in identifying individuals who may be at risk for cognitive decline.
In patients with and without dementia, amyloid-positive and negative results were significantly linked to diagnoses and treatment changes.
The genetic risk score primarily modified the risk for and onset of dementia and AD among homozygous carriers for APOE ε4.
Lower BCAA levels may be associated with an increased risk of incident dementia.
Elderly individuals without dementia who have elevated daytime sleepiness may be at greater risk for β-amyloid accumulation.
The independent data monitoring committee (IDMC) concluded that the 2 trials (AMARANTH and DAYBREAK-ALZ) investigating the treatment in mild Alzheimer’s disease dementia, were not likely to meet their primary endpoints of change from baseline on the 13-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale.
Brain autopsies of participants of the Rush Memory Aging project (n=428) were studied to identify the association between brain pathologies and total daily physical activity and mortality.
The NIA-AA has proposed updates to the 2011 guidelines for symptomatic stages of Alzheimer’s disease to include the idea that certain imaging and cerebrospinal fluid biomarkers are valid proxies for neuropathologic changes of AD.
Short-term proton pump inhibitors (PPIs) are linked to an elevated risk for hip fracture among patients with Alzheimer’s disease. No link is seem among patients taking long-term or cumulative PPIs.
